BACKGROUND AND OBJECTIVES: Few studies have evaluated the effect of the topical application of sodium alendronate (ALN) on the treatment of intrabuccal bone defects, especially those caused by periodontitis. This 6-month randomized placebo controlled clinical trial aimed at evaluating the effect of non-surgical periodontal treatment associated with the use of 1% ALN, through clinical evaluations and cone-beam computed tomography (CBCT). MATERIAL AND METHODS: Twenty individuals with chronic periodontitis underwent periodontal examination at the baseline as well as 3 and 6 months after periodontal treatment, registering clinical attachment level (CAL), periodontal probing depth (PPD), and bleeding on probing (BOP) as the clinical outcomes. After manual scaling and root planing, 40 bilateral sites with interproximal vertical bone defects were randomly treated with either 1% ALN gel or a placebo. Bone defects were evaluated through CBCT at the baseline and 6 months post-treatment. The clinical and CBCT parameters were compared using the Wilcoxon and Friedman tests (p<0.05). RESULTS: Although ALN produced a greater CAL gain when compared to the placebo at 6 months post-treatment (p=0.021), both treatments produced similar effects on the PPD, BOP, and bone height. Significant differences in bone fill were observed only in patients of the ALN group (4.5 to 3.8 mm; p=0.003) at 6 months post-treatment. CONCLUSIONS: Topical application of 1% ALN might be a beneficial adjuvant to non-surgical periodontal therapy.
BACKGROUND AND OBJECTIVES: Few studies have evaluated the effect of the topical application of sodium alendronate (ALN) on the treatment of intrabuccal bone defects, especially those caused by periodontitis. This 6-month randomized placebo controlled clinical trial aimed at evaluating the effect of non-surgical periodontal treatment associated with the use of 1% ALN, through clinical evaluations and cone-beam computed tomography (CBCT). MATERIAL AND METHODS: Twenty individuals with chronic periodontitis underwent periodontal examination at the baseline as well as 3 and 6 months after periodontal treatment, registering clinical attachment level (CAL), periodontal probing depth (PPD), and bleeding on probing (BOP) as the clinical outcomes. After manual scaling and root planing, 40 bilateral sites with interproximal vertical bone defects were randomly treated with either 1% ALN gel or a placebo. Bone defects were evaluated through CBCT at the baseline and 6 months post-treatment. The clinical and CBCT parameters were compared using the Wilcoxon and Friedman tests (p<0.05). RESULTS: Although ALN produced a greater CAL gain when compared to the placebo at 6 months post-treatment (p=0.021), both treatments produced similar effects on the PPD, BOP, and bone height. Significant differences in bone fill were observed only in patients of the ALN group (4.5 to 3.8 mm; p=0.003) at 6 months post-treatment. CONCLUSIONS: Topical application of 1% ALN might be a beneficial adjuvant to non-surgical periodontal therapy.
Authors: Amy C Killeen; Pota A Rakes; Marian J Schmid; Yijia Zhang; Nagamani Narayana; David B Marx; Jeffrey B Payne; Dong Wang; Richard A Reinhardt Journal: J Periodontol Date: 2012-03-16 Impact factor: 6.993
Authors: Ae Ra Kang; Young Rim Oh; Heung Yeol Kim; Min Jung Park; Bo Sun Joo; Won Jun Choi; Ji Young Lee; Min Hyung Jung; Yong Il Ji; Jong Soon Choi Journal: Arch Gynecol Obstet Date: 2011-11-25 Impact factor: 2.344
Authors: Francisco Javier Manzano-Moreno; Javier Ramos-Torrecillas; Elvira de Luna-Bertos; Rebeca Illescas-Montes; Timothy R Arnett; Concepción Ruiz; Olga García-Martínez Journal: Clin Oral Investig Date: 2018-06-06 Impact factor: 3.573
Authors: Claudia Arena; Vito Carlo Alberto Caponio; Khrystyna Zhurakivska; Lucio Lo Russo; Lorenzo Lo Muzio; Giuseppe Troiano Journal: BMC Oral Health Date: 2022-01-21 Impact factor: 2.757